Fortress Biotech, Inc. Form 8-K Summary
Business Context and Reporting Period
On July 25, 2024, Fortress Biotech, Inc. (the "Company") filed a Current Report on Form 8-K to disclose the entry into a new senior secured credit agreement and the termination of its existing credit facility. The Company is a biotechnology firm focused on developing and commercializing products for the treatment of rare diseases.
Key Financial Metrics and Debt Structure
- New Credit Facility: Entered into a $50.0 million senior secured credit agreement with Oaktree Fund Administration, LLC as administrative agent.
- Initial Draw: Borrowed $35.0 million on the closing date; eligible to draw an additional $15.0 million subject to lender consent.
- Interest Rate: 3-month SOFR plus 7.625% (subject to a 2.50% floor and 5.75% cap).
- Maturity: July 25, 2027, with a 30-month interest-only period.
- Repayment Schedule: 50% of the outstanding principal is due on March 31, 2027; the remaining balance is due at maturity.
- Equity Issuance: Granted lenders warrants to purchase up to 506,390 shares of common stock at an exercise price of $2.0735 per share.
- Financial Covenants:
- Minimum liquidity requirement of $7.0 million.
- Minimum net sales test for subsidiary Journey Medical Corporation of $50.0 million on a trailing 12-month basis.
Material Changes Versus Prior Period
The Company terminated its existing $60.0 million senior secured credit agreement dated August 27, 2020. The outstanding balance of $50.0 million under the prior agreement was fully prepaid on July 25, 2024, using proceeds from the new facility. The new agreement reduces the total available credit capacity from $60.0 million to $50.0 million but extends the maturity date to 2027.
Outlook, Risks, and Unusual Items
- Mandatory Prepayments: The Company must make mandatory prepayments from net cash proceeds of casualty events, asset sales, priority review voucher sales, and subsidiary distributions exceeding $5.0 million. Lenders may elect to receive warrants instead of cash in certain scenarios.
- Capital Raise Covenant: The Company is required to raise common equity or receive monetizations/distributions annually equal to the greater of $20 million or 50% of an annual budget amount, unless the loan balance is $10 million or less.
- Collateral: The Company granted a security interest in substantially all of its assets to secure the new obligations.
- Default Risks: Failure to meet the Minimum Net Sales Test or liquidity requirements constitutes an event of default, subject to cure rights.
Investor Verification Checklist
- Verify the Company's current cash balance to ensure compliance with the $7.0 million minimum liquidity covenant.
- Monitor Journey Medical Corporation's trailing 12-month net sales to assess compliance with the $50.0 million minimum sales test.
- Review the Company's ability to meet the annual capital raise covenant of $20 million or 50% of the budgeted amount.
- Assess the dilution impact of the 506,390 warrants issued to lenders, noting the anti-dilution provisions.
- Confirm the Company's strategy for the March 31, 2027, balloon payment of 50% of the principal balance.